21st Century Cures Act: Regenerative Medicine Initiative - Research Projects

Objective

The Regenerative Medicine Innovation Project (RMIP) was established by the 21st Century Cures Act to accelerate progress in the field by supporting clinical research on adult stem cells, while promoting scientific rigor and protecting patient safety. This initiative is a trans-NIH effort, in coordination with the Food and Drug Administration (FDA). Regenerative medicine is an emerging area of science that holds great promise for treating and even curing a variety of injuries and diseases. Regenerative medicine includes using stem cells and other technologies—such as engineered biomaterials and gene editing—to repair or replace damaged cells, tissues, or organs. Stem cell-based approaches are under development in labs around the world, and some have already moved into clinical trials. Such progress notwithstanding, much work remains to be done toward the development of safe and effective regenerative medicine products and to realize the full potential of this field.

Who Can Apply

• Unrestricted by Entity Type

The awardee will be a university, college, hospital, public agency, nonprofit research institution or for-profit organization that applies and receives a grant for support of research by a named principal investigator. To be eligible for funding, a grant application must be approved for scientific merit and program relevance by a scientific review group and a national advisory council.

Who Benefits

Grants and Cooperative Agreements: Average 3 to 5 years, and a maximum of 5 years. Renewals may be awarded for additional periods of up to 5 years based on competitive peer review. Method of awarding/releasing assistance: letter

Assistance Types

• Cooperative Agreement

Program Contact

pharesda@nhlbi.nih.gov
3018277968